Determinants of growth hormone receptor down-regulation.

Mol Endocrinol

Department of Cell Biology, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, Alabama 35294-0012, USA.

Published: July 2007

GH receptor (GHR) is a cytokine receptor family member that responds to GH by activation of the receptor-associated tyrosine kinase, JAK2 (Janus family of tyrosine kinase 2). We previously showed that JAK2, in addition to being a signal transducer, dramatically increases the half-life of mature GHR, partly by preventing constitutive GHR down-regulation. Herein we explored GHR and JAK2 determinants for both constitutive and GH-induced GHR down-regulation, exploiting the previously characterized GHR- and JAK2-deficient gamma2A reconstitution system. We found that JAK2's ability to protect mature GHR from rapid degradation measured in the presence of the protein synthesis inhibitor, cycloheximide, depended on the presence of GHR's Box 1 element and the intact JAK2 FERM (band 4.1/Ezrin/Radixin/Moesin); domain, but not the kinase-like or kinase domains of JAK2. Thus, GHR-JAK2 association, but not JAK2 kinase activity, is required for JAK2 to inhibit constitutive GHR down-regulation and enhance GHR half-life. In cells that expressed JAK2, but not cells lacking JAK2, GH markedly enhanced GHR degradation. Like JAK2-induced protection from constitutive down-regulation, GH-induced GHR down-regulation required the GHR Box 1 element and an intact JAK2 FERM domain. However, a JAK2 mutant lacking the kinase-like and kinase domains did not mediate GH-induced GHR down-regulation. Likewise, a kinase-deficient JAK2 was insufficient for this purpose, indicating that kinase activity is required. Both lactacystin (a proteasome inhibitor) and chloroquine (a lysosome inhibitor) blocked GH-induced GHR loss. Interestingly, GH-induced GHR ubiquitination, like down-regulation, was prevented in cells expressing a kinase-deficient JAK2 protein. Further, a GHR mutant, of which all the cytoplasmic tyrosine residues were changed to phenylalanines, was resistant to GH-induced GHR ubiquitination and down-regulation. Collectively, our data suggest that determinants required for JAK2 to protect mature GHR from constitutive degradation differ from those that drive GH-induced GHR down-regulation. The latter requires GH-induced JAK2 activation and GHR tyrosine phosphorylation and is correlated to GHR ubiquitination in our reconstitution system.

Download full-text PDF

Source
http://dx.doi.org/10.1210/me.2007-0138DOI Listing

Publication Analysis

Top Keywords

gh-induced ghr
28
ghr down-regulation
24
ghr
20
jak2
15
mature ghr
12
ghr ubiquitination
12
down-regulation
10
tyrosine kinase
8
kinase jak2
8
constitutive ghr
8

Similar Publications

Growth hormone is involved in GATA1 gene expression via STAT5B in human erythroleukemia and monocytic cell lines.

Blood Cells Mol Dis

February 2025

Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan; Clinical Research Institute for Endocrine and Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan. Electronic address:

Article Synopsis
  • GATAs are a transcription factor family with six members, where GATA1 and GATA2 are crucial for the development of specific blood cells like erythrocytes and eosinophils.
  • The study explores whether growth hormone (GH) acts as an external stimulant for GATA1 expression in blood cell lines, employing various lab techniques to assess this relationship.
  • Results indicate that GH enhances GATA1 expression through a pathway involving the GHR/JAK/STAT5 signaling mechanism, indicating its role in the proliferation of hematopoietic cells.
View Article and Find Full Text PDF
Article Synopsis
  • Excess growth hormone (GH) from pituitary adenomas can promote the development and spread of triple-negative breast cancer (TNBC).
  • In an acromegaly mouse model, researchers found that elevated GH activated TCF20, leading to the activation of NRF2-target genes that enhance TNBC metastasis.
  • Blocking GH receptors or TCF20 activity reduced tumor size and spread, indicating that targeting this signaling pathway could be a promising treatment for TNBC.
View Article and Find Full Text PDF

The Pattern of GH Action in the Mouse Brain.

Endocrinology

May 2024

Departamento de Fisiologia e Biofísica, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Sao Paulo 05508-000, Brazil.

GH acts in numerous organs expressing the GH receptor (GHR), including the brain. However, the mechanisms behind the brain's permeability to GH and how this hormone accesses different brain regions remain unclear. It is well-known that an acute GH administration induces phosphorylation of the signal transducer and activator of transcription 5 (pSTAT5) in the mouse brain.

View Article and Find Full Text PDF

Growth hormone directly stimulates GATA2 expression.

Growth Horm IGF Res

February 2024

Medicine & Clinical Science, Faculty of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan; Clinical Research Institute for Endocrine and Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Institute of Biosciences, Mukogawa Women's University, Hyogo 663-8179, Japan. Electronic address:

Article Synopsis
  • GATA2 is a crucial transcription factor for the development of specific cell types in the pituitary and blood systems, but little is known about what activates it.
  • The study explored whether growth hormone (GH) stimulates GATA2 expression in pituitary tumor cells and examined the mechanisms involved, specifically focusing on the GHR/JAK/STAT5 signaling pathway.
  • Results showed that GH boosts GATA2 levels in a dose-dependent manner through activated STAT5B, indicating that GH directly influences GATA2 and may play a role in various developmental processes.
View Article and Find Full Text PDF

Genome-wide association studies (GWAS) have identified a large number of candidate genes believed to affect longitudinal bone growth and bone mass. One of these candidate genes, , encodes a poorly characterized plasma membrane protein. Single nucleotide polymorphisms in TMEM263 are associated with bone mineral density in humans and mutations are associated with dwarfism in chicken and severe skeletal dysplasia in at least one human fetus.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!